Loading candles…
Ajanta Pharma Ltd. operates in the pharmaceutical industry, primarily engaged in developing, manufacturing, and marketing specialty pharmaceutical quality finished dosages. The company focuses on branded generic businesses across India, Asia, and Africa, and also maintains a presence in the United States generic market as well as institutional segments in Africa. Its product offerings include specialty pharmaceutical finished dosages and branded generics. Ajanta Pharma has a direct ground presence in over 30 countries and emphasizes high-margin branded generics along with a selective product strategy in regulated markets such as the US.
| Type |
|---|
| Details |
|---|
| Date |
|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 5 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 30 Jan 2026 |
| Dividend | To consider dividend | 3 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 3 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 28 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 30 Apr 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.